Cetuximab every-2-weeks versus standard weekly dosing administration schedule - supplementary material

<b>Table S1. </b>Studies evaluating cetuximab Q2W plus irinotecan in <i>KRAS</i>-unselected patients<b>Table S2. </b>Studies evaluating cetuximab Q2W plus irinotecan in patients with (<i>K)RAS</i> wt mCRC<b>Table S3. </b>Studies evaluating cetuximab Q2W plus triplet CT in patients with <i>KRAS</i> wt mCRC<b>Table S4. </b>Studies evaluating cetuximab Q2W and Q1W plus intermittent Nordic FLOX* in patients with <i>KRAS</i> exon 2 wt mCRC<b>Table S5. </b>Comparable safety with Q1W and Q2W dosing<b>Table S6. </b>Grade 3/4 AEs in special categories*<b>Table S7. </b>Studies evaluating cetuximab Q2W as first line for R/M SCCHN<br>